{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:13:49Z","timestamp":1792037629474,"version":"4.4.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"15-16","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.drudis.2006.06.001","type":"journal-article","created":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T07:13:15Z","timestamp":1153206795000},"page":"681-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Therapeutic strategies for the treatment of stroke"],"prefix":"10.1016","volume":"11","author":[{"given":"A. Richard","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashfaq","family":"Shuaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2006.06.001_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0074-7742(08)60720-5","article-title":"Development of the NMDA ion-channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury","volume":"40","author":"McBurney","year":"1997","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.drudis.2006.06.001_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(05)70202-7","article-title":"Tackling the global burden of stroke","volume":"4","author":"Editorial","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2006.06.001_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00019053-200220120-00002","article-title":"Long term cost-of-illness in stroke","volume":"20","author":"Payne","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drudis.2006.06.001_bib4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.STR.0000087149.42294.8C","article-title":"Proportion of different subtypes of stroke in China","volume":"34","author":"Zhang","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.bjp.0704449","article-title":"Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window","volume":"135","author":"Sydserff","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.06.001_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/jcbfm.1995.119","article-title":"Role of neutrophils in radical production during ischemia and reperfusion of the rat brain: effect of neutrophil depletion on extracellular ascorbyl radical formation","volume":"15","author":"Matsuo","year":"1995","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00004647-199601000-00011","article-title":"Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats","volume":"16","author":"Morimoto","year":"1996","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0006-8993(98)01124-X","article-title":"Intraluminal increase of superoxide anion following transient focal cerebral ischaemia in rats","volume":"816","author":"Mori","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","author":"NINDS rt-PA Stroke Study Group","year":"1995","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.drudis.2006.06.001_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(97)03022-5","article-title":"Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke","volume":"350","author":"Wardlaw","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2006.06.001_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0306-4522(93)90628-S","article-title":"The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat","volume":"53","author":"Snape","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2006.06.001_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0074-7742(08)60715-1","article-title":"Techniques for examining neuroprotective drugs in vivo","volume":"40","author":"Green","year":"1997","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.drudis.2006.06.001_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ilar.44.2.85","article-title":"Animal models of focal and global cerebral ischemia","volume":"44","author":"Traystman","year":"2003","journal-title":"ILAR J."},{"key":"10.1016\/j.drudis.2006.06.001_bib14","series-title":"Stroke, Vol 1: Pathophysiology, Diagnosis and Management","first-page":"377","article-title":"Middle cerebral artery","author":"Mohr","year":"1986"},{"key":"10.1016\/j.drudis.2006.06.001_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1212\/WNL.42.2.289","article-title":"Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization","volume":"42","author":"Ringelstein","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2006.06.001_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0028-3908(00)00170-2","article-title":"Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke","volume":"40","author":"Peeling","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2006.06.001_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0165-6147(03)00192-5","article-title":"Animal models of stroke: do they have value for discovering neuroprotective agents","volume":"24","author":"Green","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2006.06.001_bib18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1359-6446(05)03544-0","article-title":"What do you call 500 scientists coming together to address a productivity gap? Answer: a start","volume":"10","author":"Carney","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2006.06.001_bib19","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000179037.82647.48","article-title":"Use of animal models has not contributed to development of acute stroke therapies: Pro","volume":"36","author":"Kaste","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib20","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1161\/01.STR.0000179039.76922.e8","article-title":"Use of animal models has not contributed to development of acute stroke therapies: Con","volume":"36","author":"Fisher","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib21","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/01.STR.0000179042.06535.2f","article-title":"Stroke drug development. Usually, but not always, animal models","volume":"36","author":"Donnan","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/neur.1996.0036","article-title":"Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species","volume":"5","author":"Marshall","year":"1996","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.drudis.2006.06.001_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1161\/01.STR.32.1.190","article-title":"NXY-059, a free radical trapping agent, substantially attenuates the functional disability induced by stroke in a primate species","volume":"32","author":"Marshall","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0166-2236(99)01401-0","article-title":"Pathobiology of ischaemic stroke: an integrated view","volume":"22","author":"Dirnagl","year":"1999","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.drudis.2006.06.001_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1566524043479248","article-title":"The rise and fall of NMDA antagonists for ischemic stroke","volume":"4","author":"Hoyte","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.drudis.2006.06.001_bib26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/01.STR.32.7.1598","article-title":"Recommendations for clinical trial evaluation of acute stroke therapies","volume":"32","author":"Stroke Therapy Academic Industry Roundtable","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib27","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1161\/01.STR.30.12.2752","article-title":"Recommendations for standards regarding pre-clinical neuroprotective and restorative drug development","volume":"30","author":"Stroke Therapy Academic Industry Roundtable","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1568007053544156","article-title":"Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers","volume":"4","author":"Green","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.drudis.2006.06.001_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa052980","article-title":"NXY-059 for acute ischemic stroke","volume":"354","author":"Lees","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2006.06.001_bib30","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1097\/00001756-199911080-00004","article-title":"Thrombolysis of cerebral clot embolism in rat: effect of treatment delay","volume":"10","author":"Brinker","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.drudis.2006.06.001_bib31","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II)","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2006.06.001_bib32","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/00001756-199906230-00027","article-title":"Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats","volume":"10","author":"Brinker","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.drudis.2006.06.001_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00004647-200003000-00002","article-title":"Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats","volume":"20","author":"Asahi","year":"2000","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib34","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1161\/01.STR.31.12.3034","article-title":"Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke","volume":"31","author":"Lapchak","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib35","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.STR.0000083051.93319.28","article-title":"Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion","volume":"34","author":"Pfefferkorn","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/01.WCB.0000137868.50767.E8","article-title":"The neurotoxicity of tissue plasminogen activator?","volume":"24","author":"Kaur","year":"2004","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib37","first-page":"118","article-title":"Vampire bat plasminogen activator DSPA-\u03b11 (desmoteplase): a thrombolytic drug optimised by natural selection","volume":"31","author":"Schleuning","year":"2001","journal-title":"Haemostasis"},{"key":"10.1016\/j.drudis.2006.06.001_bib38","doi-asserted-by":"crossref","first-page":"25596","DOI":"10.1074\/jbc.270.43.25596","article-title":"Structural features mediating fibrin selectivity of vampire bat plasminogen activators","volume":"270","author":"Bringmann","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2006.06.001_bib39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/01.CIR.91.5.1540","article-title":"Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model","volume":"91","author":"Montoney","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2006.06.001_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.STR.0000149938.08731.2c","article-title":"The Desmoteplase in Acute Ischaemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase","volume":"36","author":"Hacke","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.STR.0000049764.49162.76","article-title":"Vampire bat salivary plasminogen activator (desmoteplase) - A unique fibrinolytic enzyme that does not promote neurodegeneration","volume":"34","author":"Liberatore","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib42","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/01.STR.0000166050.84056.48","article-title":"Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury","volume":"36","author":"Reddrop","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.98.11.1085","article-title":"Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb\/IIIa and \u03b1v\u03b23 integrins","volume":"98","author":"Tam","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2006.06.001_bib44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1055\/s-0037-1615765","article-title":"7E3 f(ab\u2032)2 an effective antagonist of rat \u03b1IIb\u03b23 and \u03b1v\u03b23, blocks in vivo thrombus formation and in vitro angiogenesis","volume":"85","author":"Sassoli","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2006.06.001_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004647-200202000-00009","article-title":"Glycoprotein IIb\/IIIa antagonist, murine 7E3 f(ab\u2032)2 and tissue plasminogen activator in focal ischemia: Evaluation of efficacy and risk of hemorrhage with combination therapy","volume":"22","author":"Shuaib","year":"2002","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib46","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/01.CIR.0000068374.57764.EB","article-title":"Adjuvant treatment with a glycoprotein IIb\/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke","volume":"107","author":"Zhang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2006.06.001_bib47","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/01.STR.0000147963.68238.da","article-title":"Intravenous administration of a GPIIb\/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model","volume":"35","author":"Zhang","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib48","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.283.18.2395","article-title":"Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomised controlled trial. Stroke treatment with ancrod trial","volume":"283","author":"Sherman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2006.06.001_bib49","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in acute cerebral thromboembolism","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA."},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2006.06.001_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000074806","article-title":"Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: What is the next step?","volume":"17","author":"Sherman","year":"2004","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.drudis.2006.06.001_bib51","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/01.STR.0000185730.50480.e7","article-title":"Intravenous heparin started within the first 3hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions","volume":"36","author":"Camerlingo","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2003.07.003","article-title":"Nitrones as neuroprotective agents in cerebral ischemia, with particular reference in NXY-059","volume":"100","author":"Green","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2006.06.001_bib53","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1021\/jm00016a017","article-title":"(1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses","volume":"38","author":"Chenard","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2006.06.001_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1568007053544183","article-title":"NMDA\/NR2B selective antagonists in the treatment of ischaemic brain injury","volume":"4","author":"Wang","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.drudis.2006.06.001_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(97)10092-9","article-title":"CP-101,606, a potent neuroprotectant selective for forebrain neurons","volume":"331","author":"Menniti","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.06.001_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/089771504772695977","article-title":"The NMDA NR2B subunit selective receptor antagonist CP-101,606, enhances the functional recovery and reduces brain damage after cortical compression-induced brain ischemia","volume":"21","author":"Kundrotiene","year":"2004","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.drudis.2006.06.001_bib57","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/01.STR.28.11.2244","article-title":"Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-d-aspartate receptor, on the volume of ischaemic brain damage and cytotoxic brain edema after middle cerebral artery occlusion in the feline brain","volume":"28","author":"Di","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3171\/jns.2003.98.2.0397","article-title":"Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats","volume":"98","author":"Yang","year":"2003","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.drudis.2006.06.001_bib59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/307462a0","article-title":"Magnesium gates glutamate-activated channels in mouse central neurones","volume":"307","author":"Nowak","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2006.06.001_bib60","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0024-3205(02)01738-1","article-title":"Effects of magnesium sulphate on energy metabolites and glutamate in the cortex during focal ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique","volume":"71","author":"Lin","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2006.06.001_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00006123-199901000-00100","article-title":"Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischaemia","volume":"44","author":"Schmid-Elsaesser","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/j.drudis.2006.06.001_bib62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3171\/jns.1996.85.1.0117","article-title":"Neuroprotective effects of preischemia intra-arterial magnesium sulfate in reversible cerebral ischemia J","volume":"85","author":"Marinov","year":"1996","journal-title":"Neurosurg."},{"key":"10.1016\/j.drudis.2006.06.001_bib63","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jcbfm.1991.170","article-title":"Reduction in infarct volume by magnesium after middle cerebral artery occlusion in rats","volume":"11","author":"Izumi","year":"1991","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3940(00)01048-X","article-title":"Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulphate in embolic stroke model of rat","volume":"285","author":"Yang","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.drudis.2006.06.001_bib65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(04)15490-1","article-title":"Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial","volume":"363","author":"Lees","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2006.06.001_bib66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1358\/dof.1998.023.01.442870","article-title":"Identification and pharmacological characterization of GV 150526, a novel glycine antagonist as a potent neuroprotective agent","volume":"23","author":"Di Fabio","year":"1998","journal-title":"Drugs Future"},{"key":"10.1016\/j.drudis.2006.06.001_bib67","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1001\/jama.285.13.1719","article-title":"Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial","volume":"285","author":"Sacco","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2006.06.001_bib68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1568007053544129","article-title":"AMPA receptor agonists for the treatment of stroke. Treatment of ischaemic brain injury","volume":"4","author":"Weiser","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.drudis.2006.06.001_bib69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1568007053544093","article-title":"Glutamate transporters as drug targets","volume":"4","author":"Hinoi","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.drudis.2006.06.001_bib70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0028-3908(85)90153-4","article-title":"The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a model of presynaptic 5-HT1 function","volume":"24","author":"Goodwin","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2006.06.001_bib71","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.jcbfm.9600038","article-title":"Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury","volume":"25","author":"Mauler","year":"2005","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0960-894X(01)00008-7","article-title":"New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischaemic effects","volume":"11","author":"Kamei","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2006.06.001_bib73","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ddr.10083","article-title":"Metal ion chelation in neurodegenerative disorders","volume":"56","author":"Angel","year":"2002","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib74","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.272.5264.1013","article-title":"The role of zinc in selective neuronal death after transient global cerebral ischaemia","volume":"272","author":"Koh","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.drudis.2006.06.001_bib75","article-title":"The lipophilic transition modulator DP-b99 attenuates oxidative stress-induced neuronal death","author":"Friedman","year":"2004","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.drudis.2006.06.001_bib76","article-title":"The lipophilic transition modulator DP-b99 attenuates matrix metalloproteinase activity in a rat MCAO ischaemic model","author":"Angel","year":"2004","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.drudis.2006.06.001_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.2005.02378.x","article-title":"Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans","volume":"60","author":"Rosenberg","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2006.06.001_bib78","article-title":"A novel neuroprotectant, PAN-811, decreases infarct volume following transient focal ischemia in rats","author":"Lu","year":"2004","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.drudis.2006.06.001_bib79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainresrev.2003.10.002","article-title":"A potentially critical role of phospholipases in central nervous system ischemic, traumatic and neurodegenerative disorders.","volume":"44","author":"Phillis","year":"2004","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.drudis.2006.06.001_bib80","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/BF00965041","article-title":"Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil","volume":"6","author":"Trovarelli","year":"1981","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib81","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.0.CO;2-B","article-title":"CDP-choline: neuroprotection in transient forebrain ischemia of gerbils","volume":"58","author":"Rao","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jnr.10403","article-title":"Citicoline mechanisms and clinical efficacy in cerebral ischemia","volume":"70","author":"Adibhatla","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib83","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/01.STR.19.2.217","article-title":"Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia","volume":"19","author":"Kakihana","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0306-4522(02)00912-0","article-title":"Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia","volume":"118","author":"Sobrado","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2006.06.001_bib85","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1006\/exnr.1999.7314","article-title":"Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: Neuroprotective effects when used alone or in combination with urokinase","volume":"161","author":"Shuaib","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2006.06.001_bib86","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.STR.0000038691.03334.71","article-title":"Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials","volume":"33","author":"D\u00e1valos","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib87","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00004647-200206000-00011","volume":"22","author":"Tateishi","year":"2002","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1568007053544084","article-title":"Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocyte overproduction of S100\u03b2","volume":"4","author":"Asano","year":"2005","journal-title":"Curr Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.drudis.2006.06.001_bib89","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1750-3639.1999.tb00214.x","article-title":"Oxidative stress in brain ischemia","volume":"9","author":"Love","year":"1999","journal-title":"Brain Pathol."},{"key":"10.1016\/j.drudis.2006.06.001_bib90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004647-200101000-00002","article-title":"Reactive oxygen radicals in signalling and damage in the ischemic brain","volume":"21","author":"Chan","year":"2001","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2006.06.001_bib91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0006-2952(92)90035-H","article-title":"Action of ebselen as an antioxidant against lipid peroxidation","volume":"44","author":"Noguchi","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2006.06.001_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2004.05.024","article-title":"Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia","volume":"495","author":"Salom","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.06.001_bib93","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/01.STR.23.6.894","article-title":"Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats","volume":"23","author":"Xue","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib94","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/10715760100300351","article-title":"Comparison of the radical trapping ability of PBN, S-PBN and NXY-059","volume":"34","author":"Maples","year":"2001","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib95","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00004647-199907000-00008","article-title":"Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischaemia in the rat","volume":"19","author":"Kuroda","year":"1999","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"10.1016\/j.drudis.2006.06.001_bib96","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/01.STR.0000087790.79851.A8","article-title":"Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4hours after occlusion","volume":"34","author":"Marshall","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib97","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/01.STR.0000053032.14223.81","article-title":"Tolerability of NXY-059 at higher target concentrations in patients with acute stroke","volume":"34","author":"Lees","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib98","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-8993(02)02922-0","article-title":"NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia","volume":"947","author":"Yoshimoto","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib99","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0006-8993(02)02286-2","article-title":"Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A","volume":"932","author":"Yoshimoto","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ana.10659","article-title":"Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia","volume":"54","author":"Ginsberg","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2006.06.001_bib101","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1124\/jpet.105.083386","article-title":"Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics","volume":"313","author":"Ley","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2006.06.001_bib102","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.brainres.2005.12.035","article-title":"Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia","volume":"1072","author":"Green","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib103","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMp058312","article-title":"Stroke and neurovascular protection","volume":"354","author":"del Zoppo","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2006.06.001_bib104","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1517\/13543784.9.10.2281","article-title":"Therapeutic potential of anti-inflammatory drugs in focal stroke","volume":"9","author":"Barone","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2006.06.001_bib105","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/35094583","article-title":"Cytokines and acute neurodegeneration","volume":"2","author":"Allan","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drudis.2006.06.001_bib106","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.STR.28.6.1233","article-title":"Tumor necrosis factor-alpha - a mediator of focal ischemic brain injury","volume":"28","author":"Barone","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib107","first-page":"178","article-title":"Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage","volume":"5","author":"Relton","year":"1993","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"key":"10.1016\/j.drudis.2006.06.001_bib108","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/nm1202-1363","article-title":"The many faces of tumor necrosis factor in stroke","volume":"8","author":"Hallenbeck","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2006.06.001_bib109","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.expneurol.2005.07.024","article-title":"TNF-alpha antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain","volume":"196","author":"Heldmann","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2006.06.001_bib110","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients","volume":"76","author":"Emsley","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.drudis.2006.06.001_bib111","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1568007053544147","article-title":"Therapeutic potential of TACE inhibitors in stroke","volume":"4","author":"Lovering","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.drudis.2006.06.001_bib112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1568007053544101","article-title":"Growth factor treatment of stroke","volume":"4","author":"Ren","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.drudis.2006.06.001_bib113","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1161\/01.STR.0000071760.66720.5F","article-title":"Fibroblast growth factor-18 reduced infarct volumes and behavioural deficits after transient occlusion of the middle cerebral artery in rats","volume":"34","author":"Ellsworth","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib114","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0006-8993(98)00674-X","article-title":"The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischaemia in rats","volume":"804","author":"Huh","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-2999(01)01255-9","article-title":"Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies","volume":"428","author":"Liu","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.06.001_bib116","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.STR.32.2.553","article-title":"Human albumin therapy of acute ischemic stroke, marked neuroprotective efficacy at moderate doses and with a broad therapeutic window","volume":"32","author":"Belayev","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib117","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1385\/NCC:1:3:335","article-title":"High dose serum albumin for the treatment of acute ischemic stroke \u2013 a safety study","volume":"1","author":"Koch","year":"2004","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.drudis.2006.06.001_bib118","first-page":"420","article-title":"The ALIAS phase I trial: a dose-escalation and safety study of albumin for acute ischemic stroke","volume":"36","author":"Ginsberg","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib119","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.expneurol.2004.05.006","article-title":"Extending the window for acute ischaemic stroke treatment: thrombolytics plus CNS protective therapies","volume":"188","author":"Wagner","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2006.06.001_bib120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbr.2005.03.023","article-title":"Assessing combination treatments for acute stroke: preclinical experiences","volume":"162","author":"Lu","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.drudis.2006.06.001_bib121","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.STR.0000015346.00054.8B","article-title":"Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (Generic NXY-059) in rabbit small clot embolic stroke model","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib122","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/01.STR.0000017145.22806.AA","article-title":"Effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (Generic NXY-059) on intracerebral haemorrhage in a rabbit large clot embolic stroke model","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2006.06.001_bib123","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1359-6446(04)03251-9","article-title":"Targeting JNK3 for the treatment of neurodegenerative disorders","volume":"9","author":"Resnick","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2006.06.001_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.10119","article-title":"Cellular response to oxidative stress: signalling for suicide and survival","volume":"192","author":"Martindale","year":"2002","journal-title":"J. Cell. Physiol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644606001838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644606001838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:56:58Z","timestamp":1761220618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644606001838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":124,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S1359644606001838"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2006.06.001","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies for the treatment of stroke","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2006.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}